Core Viewpoint - The article highlights the recent approval of seven innovative medical devices by the National Medical Products Administration, indicating a growing focus on medical technology innovation in China [1]. Group 1: Company Profiles - Zhihui Heart Medical Technology Co., Ltd., a subsidiary of Peijia Medical Group, focuses on the development and production of shock wave therapy systems for complex vascular diseases, with a total investment of 450 million yuan and projected annual revenue of 500 million yuan upon completion [3]. - General Electric Medical Systems (Tianjin) Co., Ltd. is a major MRI production base for GE globally, with plans to invest 500 million yuan in a research center over the next five years, enhancing its capabilities in superconducting magnets and high-field MRI technology [6]. - Shandong Weigao Orthopedic Materials Co., Ltd. specializes in orthopedic medical devices and has a comprehensive product line, being one of the leading companies in the domestic orthopedic industry [7]. - Henan Randshitan Gene Technology Co., Ltd. focuses on gene diagnosis and treatment technology, with a recent patent application for a kit that detects drug metabolism genes [8]. - Shanghai Huanqing Medical Technology Co., Ltd. is developing an innovative ventricular assist device for acute heart failure treatment, with plans for clinical trials following successful animal testing [9]. - Suzhou Hechun Medical Technology Co., Ltd. specializes in chronic disease management devices, including an innovative insulin pump and a closed-loop artificial pancreas system [10]. - Yuanxin Technology (Shenzhen) Co., Ltd. is the only company developing iron-based absorbable vascular stents, with significant funding rounds and clinical approvals in multiple regions [11]. Group 2: Product Approvals - Seven innovative medical devices have been approved for special review, reflecting the regulatory support for advancements in medical technology [1]. - The devices include a shock wave valve treatment system, MRI systems, and various orthopedic and gene testing products, showcasing a diverse range of applications in the medical field [4][8][10].

正式报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 现有取得注册证产品： 取石网篮、肠道支架及输送系统、胆道支架及输送系统、颅内支撑导管等。 2024年临床项目处于快速有序进行中，并以计划启动"下静脉取栓装置用于治疗深静脉血栓形成的安全性和有效性的前瞻性、多中心、随机、开放、平行对 照、非劣效临床试验"。 2025年4月27日，NMPA公布了创新医疗器械特别审查申请审查结果公示（2025年第4号），有9款产品进入创新通道。 1. 产品名称：颅内静脉窦取栓支架 申请人：北京弘海微创科技有限公司 北京弘海微创科技有限公司成立于2017年11月份，是一家以植/介入医疗器械研发、生产、销售于一体的创新型平台公司，聚焦于神经、外周、消化、泌 尿、呼吸等植/介入领域的医疗器械研发，为医患提供完整的治疗方案。公司拥有全球独创的工艺技术，通过自主研发的设备，开发出具有卓越性能的植/介 入医疗器械。 2. 结核分枝杆菌复合群耐药基因突变检测试剂盒（可逆末端终止测序法） 申请人：广州市金圻睿生物科技有限责任公司 广州市金圻睿生物科技有限责任公司（简称"金圻睿"）于2016年成立，聚焦于精准医疗体 ...